Gonadotropin-releasing hormone agonist treatment of girls with constitutional short stature and normal pubertal development.

Carel JC, Hay F, Coutant R, Rodrigue D, Chaussain JL

The Journal of clinical endocrinology and metabolism1 Sept 1996Cited by 30 (Europe PMC)

PMID8784090DOI10.1210/jcem.81.9.8784090PepBankPUB-08784090

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialEfficacy outcome
In girls with short stature, bone age progressed by 0.6 +/- 0.3 bone age yr/yr during triptorelin treatment.
In plain wordsIn girls with short stature, bone age progressed by 0.6 +/- 0.3 bone age yr/yr during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedBone age progression during treatment
Study
n = 31
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Bone age progression
0.6 bone age yr/yr
during treatment
Source sentences
Summary
During the 23 +/- 4 months of treatment, bone age progression was 0.6 +/- 0.3 bone age yr/yr, and growth velocity declined from 7 +/- 2 to 4 +/- 0.8 cm/yr (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409001
02HumanNon-randomized trialEfficacy outcome
In girls with short stature, growth velocity declined from 7 +/- 2 to 4 +/- 0.8 cm/yr during triptorelin treatment.
In plain wordsIn girls with short stature, growth slowed during triptorelin treatment compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseGrowth velocity during treatment
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Growth velocity
7 cm/yr
baseline
Growth velocity
4 cm/yr
during treatment
Source sentences
Summary
During the 23 +/- 4 months of treatment, bone age progression was 0.6 +/- 0.3 bone age yr/yr, and growth velocity declined from 7 +/- 2 to 4 +/- 0.8 cm/yr (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409002
03HumanNon-randomized trialEfficacy outcome
In girls with short stature, height prognosis increased from 149.6 +/- 3.4 to 151.8 +/- 4 cm during triptorelin treatment.
In plain wordsIn girls with short stature, predicted height increased during triptorelin treatment compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHeight prognosis at treatment end
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Height prognosis
149.6 cm
baseline
Height prognosis
151.8 cm
end of treatment
Height prognosis change
2.2 cm
end of treatment versus baseline
Source sentences
Summary
Height prognosis, calculated by the Bayley-Pinneau method, progressed from 149.6 +/- 3.4 to 151.8 +/- 4 cm at the end of treatment (+2.2 +/- 2.6 cm; P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409003
04HumanNon-randomized trialEfficacy outcome
In girls with short stature, growth velocity increased to 4.6 +/- 1.6 cm/yr after triptorelin withdrawal.
In plain wordsIn girls with short stature, growth increased after triptorelin withdrawal compared with during treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseGrowth velocity after withdrawal
Study
n = 31
Comparator
Growth velocity during treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Growth velocity after withdrawal
4.6 cm/yr
after treatment interruption
Source sentences
Summary
When treatment was interrupted, growth velocity slightly increased to 4.6 +/- 1.6 cm/yr, and bone age maturation was accelerated: 1.3 +/- 0.4 bone age yr/yr during the first posttreatment year.
1 context sentence(design, population, supporting numbers)
Summary · context
During the 23 +/- 4 months of treatment, bone age progression was 0.6 +/- 0.3 bone age yr/yr, and growth velocity declined from 7 +/- 2 to 4 +/- 0.8 cm/yr (P < 0.0001).
Report a problemFND-0878409004
05HumanNon-randomized trialEfficacy outcome
In girls with short stature, bone maturation accelerated to 1.3 +/- 0.4 bone age yr/yr after triptorelin withdrawal.
In plain wordsIn girls with short stature, bone maturation accelerated after triptorelin withdrawal compared with during treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBone maturation after withdrawal
Study
n = 31
Comparator
Bone age progression during treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Bone age progression after withdrawal
1.3 bone age yr/yr
first posttreatment year
Source sentences
Summary
When treatment was interrupted, growth velocity slightly increased to 4.6 +/- 1.6 cm/yr, and bone age maturation was accelerated: 1.3 +/- 0.4 bone age yr/yr during the first posttreatment year.
1 context sentence(design, population, supporting numbers)
Summary · context
During the 23 +/- 4 months of treatment, bone age progression was 0.6 +/- 0.3 bone age yr/yr, and growth velocity declined from 7 +/- 2 to 4 +/- 0.8 cm/yr (P < 0.0001).
Report a problemFND-0878409005
06HumanNon-randomized trialEfficacy outcome
In girls previously treated with triptorelin, bone age at the last visit was 14.9 +/- 1.3 yr.
In plain wordsIn girls previously treated with triptorelin, bone age at the last visit was 14.9 +/- 1.3 yr.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedBone age at last visit
Study
n = 31
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Bone age at last visit
14.9 yr
last visit
Bone age at last visit, all patients
≥ 13.5 yr
all patients
Source sentences
Summary
At the last visit, 26 +/- 9 months after interruption of treatment, bone age was 14.9 +/- 1.3 yr (> or = 13.5 yr in all patients), height was 149.1 +/- 4 cm, and final height prognosis was 150.6 +/- 3.6 cm.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409006
07HumanNon-randomized trialEfficacy outcome
In girls previously treated with triptorelin, height at the last visit was 149.1 +/- 4 cm.
In plain wordsIn girls previously treated with triptorelin, height at the last visit was 149.1 +/- 4 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedHeight at last visit
Study
n = 31
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Height at last visit
149.1 cm
last visit
Source sentences
Summary
At the last visit, 26 +/- 9 months after interruption of treatment, bone age was 14.9 +/- 1.3 yr (> or = 13.5 yr in all patients), height was 149.1 +/- 4 cm, and final height prognosis was 150.6 +/- 3.6 cm.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409007
08HumanNon-randomized trialEfficacy outcome
In girls previously treated with triptorelin, final height prognosis was 150.6 +/- 3.6 cm.
In plain wordsIn girls previously treated with triptorelin, predicted final height was 150.6 +/- 3.6 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedFinal height prognosis
Study
n = 31
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Final height prognosis
150.6 cm
last visit
Source sentences
Summary
At the last visit, 26 +/- 9 months after interruption of treatment, bone age was 14.9 +/- 1.3 yr (> or = 13.5 yr in all patients), height was 149.1 +/- 4 cm, and final height prognosis was 150.6 +/- 3.6 cm.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409008
09HumanNon-randomized trialEfficacy outcome
In girls treated with triptorelin, final height prognosis exceeded pretreatment prognosis by 1 +/- 2.3 cm.
In plain wordsIn girls treated with triptorelin, final predicted height exceeded pretreatment predicted height by 1 +/- 2.3 cm.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseFinal versus pretreatment height prognosis
Study
n = 31
Comparator
Pretreatment height prognosis
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Final minus pretreatment height prognosis
1 cm
final prognosis versus pretreatment
Source sentences
Summary
Final height prognosis was 1 +/- 2.3 cm greater than pretreatment height prognosis (P < 0.02) and 1.2 +/- 2.2 cm below the height predicted at the end of the treatment (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409009
10HumanNon-randomized trialEfficacy outcome
In girls treated with triptorelin, final height prognosis was 1.2 +/- 2.2 cm below treatment-end prognosis.
In plain wordsIn girls treated with triptorelin, final predicted height was below the prediction at treatment end.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseFinal versus treatment-end height prognosis
Study
n = 31
Comparator
Height predicted at the end of treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Final minus treatment-end height prognosis
−1.2 cm
final prognosis versus prognosis at end of treatment
Source sentences
Summary
Final height prognosis was 1 +/- 2.3 cm greater than pretreatment height prognosis (P < 0.02) and 1.2 +/- 2.2 cm below the height predicted at the end of the treatment (P < 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409010
11HumanNon-randomized trialSafety outcome
In girls with short stature, no major side effect was observed with triptorelin.
In plain wordsIn girls with short stature, no major side effect was observed with triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Direction not reportedMajor side effects
Study
n = 31
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Source sentences
Summary
No major side-effect was observed.
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409011
12HumanNon-randomized trialEfficacy outcome
In girls with short stature, height SD score decreased from -2.3 +/- 0.9 to -2.7 +/- 0.7 during triptorelin treatment.
In plain wordsIn girls with short stature, height SD score decreased during triptorelin treatment compared with before treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseHeight SD score
Study
n = 31
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 23 +/- 4 monthsAs given in this study (human).
Measurements
Height SD score
−2.3 SD score
baseline
Height SD score
−2.7 SD score
during treatment
Source sentences
Summary
Height SD score decreased during treatment with GnRH agonist from -2.3 +/- 0.9 to -2.7 +/- 0.7 SD score (P < 0.0001).
1 context sentence(design, population, supporting numbers)
Summary · context
We treated 31 girls, aged 11.9 +/- 1 yr (mean +/- SD), with short stature, recent pubertal onset and predicted final height of 155 cm or less with depot triptorelin.
Report a problemFND-0878409012

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.